What a skin booster is, and is not
Skin boosters occupy the space between skincare and structural injectables. The defining idea: inject a material into or just under the dermis not to build shape, but to change the behaviour and quality of the skin itself, its hydration, elasticity, thickness and light reflection. Nothing is lifted, nothing is volumised, and a well-treated face should look like the same face on a very good day.
That modesty is both the category's appeal and its marketing problem. Because results are diffuse and gradual, they are hard to photograph and easy to oversell, and the sector has responded with language, regeneration, remodelling, "skin health", that runs some distance ahead of what trials measure. This review takes the category on its own terms: what is in it, what each part can demonstrate, and what a buyer should expect.
The main product families
| Family | Example approach | Proposed action | Reversible |
|---|---|---|---|
| Low or lightly cross-linked hyaluronic acid | Profhilo and similar high-concentration HA | Deep hydration plus claimed bioremodelling of collagen and elastin | Yes, with hyaluronidase |
| Microdroplet HA skin boosters | Multiple small dermal deposits across an area | Sustained dermal hydration | Yes |
| Polynucleotides | Purified DNA fragments, usually fish-derived | Fibroblast stimulation, improved tissue environment | No, resorbs naturally |
| Amino acid and peptide blends | Injectable cocktails with HA carriers | Substrate provision for collagen synthesis | Partially |
| Exosome and cell-derived products | Topical after microneedling, some injected abroad | Signalling-based stimulation | No |
These are meaningfully different technologies sharing a shelf. A patient quoted for "skin boosters" should always ask which product, because the evidence, the price and the biological plausibility differ family by family. Polynucleotides in particular have enough of their own literature that we assess them separately in our dedicated review.
What the evidence supports
Taking the category as a whole, the published human evidence supports a consistent but bounded set of claims.
- Hydration improves. Instrumental measures of skin hydration rise after HA-based courses, reliably and unsurprisingly, since hyaluronic acid binds water. Effect persists for some months after a course.
- Elasticity measures improve modestly. Several small trials of high-concentration HA products and of polynucleotides report improved elasticity and firmness scores at one to six months.
- Patients notice. Patient-reported outcomes and blinded photographic assessments generally favour treatment over baseline for glow, texture and fine crepiness.
- Safety is good. Adverse events across the category are dominated by bruising, transient bumps at injection points and short-lived swelling.
The standard limitations apply with full force. Trials are small, frequently in the tens of patients, often unblinded, often manufacturer-supported, and rarely compare one booster with another or with cheaper alternatives such as a course of microneedling or well-evidenced topicals. Follow-up seldom exceeds six to twelve months. Histological evidence of new collagen exists but is thinner than the marketing implies, and "bioremodelling" remains a brand concept, not a defined biological endpoint. Independent appraisal of the kind NICE applies to medical interventions simply does not exist for this category, and products reach market through device-style CE or UKCA routes overseen by the MHRA rather than through medicine-grade efficacy trials.
The category's evidence supports better-hydrated, slightly springier skin for a few months. Everything beyond that is a hypothesis with a price tag.
Protocols: courses, intervals, maintenance
Almost every product in the category is protocolised as a course, typically two to three initial sessions spaced two to four weeks apart, then maintenance every four to nine months. The course structure is partly biological, cumulative stimulation being the stated aim, and partly commercial. Injection techniques vary from a handful of bolus points per side of the face to dozens of microdroplets, with treatment commonly extended to the neck, hands and décolletage, areas where structural injectables have little to offer and boosters arguably earn their keep most clearly.
Expect visible bumps for a day or two with some techniques, bruising as with any injectable, and results assessed properly only at four or more weeks after the final session of a course.
Cost across the category
Observed UK pricing in 2026 runs from roughly £150 to £350 per session for microdroplet HA boosters, £250 to £450 per session for the high-concentration HA products and polynucleotides, with full initial courses therefore commonly landing between £500 and £1,350. Exosome-adjacent treatments price erratically, £400 to £900 per session, with the thinnest evidence in the category behind them. Wider context sits in our 2026 UK price survey. A course of skin boosters costs about the same as a course of medical-grade microneedling or a good fractionated laser session, which are its true competitors, and any consultation that does not mention those alternatives is a sales conversation.
Who benefits most
The strongest candidates share a profile: skin that looks dull, dehydrated, finely crinkled or tired, on a face that does not need volume or lifting. That includes younger patients with early texture change, older patients who have appropriate volume but poor skin quality, and the neck, chest and hands at almost any age. Smokers, sun-damaged skin and recent significant weight loss all blunt results. The weakest candidates are those hoping a booster will substitute for filler, toxin or an energy device; it will not, and a practitioner who says so early is worth keeping. Boosters also pair sensibly after structural work, for instance improving skin quality where laxity itself needs an energy-based treatment or surgery.
Where the claims outrun the data
Three claims deserve standing scepticism. "Regenerates skin" implies durable structural renewal that no trial in this category has demonstrated beyond months. "Stimulates collagen for long-term anti-ageing" extrapolates from short-term elasticity measures and in-vitro work. And "results last up to X months" typically cites the longest observed follow-up, not the typical patient's experience. None of this makes boosters a bad purchase; hydration and glow are real, wanted and delivered. It makes them a product to buy with accurate expectations, from a regulated professional you have checked on a register such as the GMC's or through Save Face, at a price that reflects a few months of better skin rather than a biological reset. On those terms, the category earns its place. On the terms of its own advertising, it does not yet.